Sandip Manku

Background

About Sandip Manku

Founder & Director, Pro Pharmaceuticals Group (ProPG)| Accelerating Access. Transforming Lives.I founded Pro Pharmaceuticals Group (ProPG) in 2015 to tackle one of healthcare’s toughest challenges: ensuring patients and hospitals can access critical medicines when traditional supply chains fail.Trusted by hospitals across Australia to secure essential medicines when conventional supply chains break down, ProPG has developed deep expertise in regulatory pathways, global sourcing, and cold-chain logistics for time-critical therapies.Today, ProPG operates across four core pillars:• Unlicensed Medicines – Supplying therapies under Australia’s Special Access Scheme (SAS) and Section 19A pathways.• Drug Shortage Response – Rapid solutions for hospitals facing critical medicine shortages.• Comparator & Clinical Trial Supply – Reliable sourcing of reference listed drugs (RLDs) for CROs, CMOs, and sponsors worldwide.• Global Health Access – Supporting public health programs and international partners working to expand access to essential medicines.In addition to our work with hospitals and clinical trial partners, ProPG contributes to global health initiatives and is proud to support tuberculosis treatment programs through collaboration with the Global Drug Facility. Ensuring reliable access to TB medicines remains a critical part of global efforts to combat one of the world’s most serious infectious diseases.Over the past decade, we have built a trusted global sourcing network spanning Europe, Asia, North America Australasia and other areas, enabling rapid, compliant access to medicines when time and reliability matter most.Alongside our supply operations, we are investing in digital infrastructure and regulatory assets to strengthen long-term medicine access:• CheckMed.ai – global shortages intelligence platform• ProTrack – real-time operational logistics system• ProPortal – hospital access platform for streamlined procurementThrough these platforms and partnerships, our goal is simple:to build a resilient pharmaceutical access infrastructure that ensures patients receive the medicines they need, wherever and whenever supply gaps occur.If you are a hospital, CRO, pharmaceutical company, or global health partner facing complex medicine access challenges — I welcome the opportunity to connect.